Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. on August 9, 2012. The filing serves to announce the company's financial results for the fiscal quarter ended June 30, 2012. The detailed results are contained in the press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text provided for analysis.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of a press release containing the quarterly results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor subject to the liabilities of that section. It further states the information is not incorporated by reference into other filings unless expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed in the text of the 8-K itself.
Investor Verification Checklist
- Review the full text of the Earnings Press Release (Exhibit 99.1) for specific revenue and net income figures for the quarter ended June 30, 2012.
- Verify year-over-year and quarter-over-quarter performance metrics not present in the 8-K summary.
- Check for any forward-looking statements or updated financial guidance included in the press release.
- Confirm the status of the company's cash position and liquidity as reported in the full earnings release.